A Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Subjects With IgE ≥ 30 IU/mL.

Trial Profile

A Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Subjects With IgE ≥ 30 IU/mL.

Completed
Phase of Trial: Phase I

Latest Information Update: 03 Feb 2016

At a glance

  • Drugs MEDI 4212 (Primary) ; MEDI 4212 (Primary) ; Omalizumab
  • Indications Allergic asthma; Allergic rhinitis; Atopic dermatitis
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 03 Feb 2016 Results published in the Advances in Therapy
    • 18 Dec 2014 Protocol has been amended to increase treatment arms from 3 to 8,drug regimen, primary endpoint assessment time, inclusion/exclusion criteria.
    • 01 Jun 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top